🇺🇸 FDA
Pipeline program

Imatinib Mesylate Tablets, 400 mg

ARL/CT/13/001

Phase 3 small_molecule completed

Quick answer

Imatinib Mesylate Tablets, 400 mg for Chronic Myeloid Leukemia is a Phase 3 program (small_molecule) at Amneal Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Amneal Pharmaceuticals
Indication
Chronic Myeloid Leukemia
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials